Eagle Pharmaceuticals Announces Divestiture of Barhemsys
Eagle Pharmaceuticals Announces Divestiture of Barhemsys GlobeNewswire January 14, 2026 WOODCLIFF LAKE, N.J., Jan. 14, 2026 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the divestiture of the marketing authorization for Barhemsys (amisulpride) in the U.S. to LXO Group, Paris, France. Barhemsys is used for the treatment […]